Literature DB >> 33378967

Research progress on the role of gal-3 in cardio/cerebrovascular diseases.

Zhan-Qi Cao1, Xin Yu1, Ping Leng2.   

Abstract

Galectin-3 (gal-3), a member of the galectin family, is a glycoprotein with high affinity for β-galactoside. Gal-3 is a cytoplasmically synthesized protein that can shuttle between the cytoplasm and nucleus and can even be transported to the membrane and secreted into the extracellular environment. Cardio/cerebrovascular diseases generally refer to ischemic or hemorrhagic diseases occurring in the heart, brain and systemic tissues, which are characterized by high morbidity, high disability rates and high mortality rates. To date, considerable research has demonstrated that gal-3 expression is aberrantly increased and plays important roles in cardio/cerebrovascular diseases, such as acute ischemic stroke (AIS), myocardial fibrosis, acute coronary syndrome (ACS), and heart failure (HF). Hence, understanding the biological roles of gal-3 in these diseases may be essential for cardio/cerebrovascular disease treatment and diagnosis to improve patient quality of life. In this review, we summarize current research on the roles of gal-3 in human cardiovascular diseases and potential inhibitors of gal-3, which may provide new strategies for disease therapies.
Copyright © 2020 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Aberrantly increased; Cardio/cerebrovascular diseases; Galectin-3; Inhibitors

Mesh:

Substances:

Year:  2020        PMID: 33378967     DOI: 10.1016/j.biopha.2020.111066

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  4 in total

1.  Novel Galectin-3 Inhibitors for Treating Fibrosis.

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2021-01-11       Impact factor: 4.345

2.  Plasma galectin-3 concentration and estimated glomerular filtration rate in patients with type 2 diabetes with and without albuminuria.

Authors:  Jin Ook Chung; Seon-Young Park; Seung Baek Lee; Na-Ri Kang; Dong Hyeok Cho; Dong Jin Chung; Min Young Chung
Journal:  Sci Rep       Date:  2022-09-29       Impact factor: 4.996

Review 3.  The Diagnostic and Therapeutic Potential of Galectin-3 in Cardiovascular Diseases.

Authors:  Grażyna Sygitowicz; Agata Maciejak-Jastrzębska; Dariusz Sitkiewicz
Journal:  Biomolecules       Date:  2021-12-29

4.  Impact of prior cerebrovascular disease and glucose status on incident cerebrovascular disease in Japanese.

Authors:  Momoko Oe; Kazuya Fujihara; Mayuko Harada-Yamada; Taeko Osawa; Masaru Kitazawa; Yasuhiro Matsubayashi; Takaaki Sato; Yuta Yaguchi; Midori Iwanaga; Hiroyasu Seida; Takaho Yamada; Hirohito Sone
Journal:  Cardiovasc Diabetol       Date:  2021-09-03       Impact factor: 9.951

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.